FIELD: pharmaceuticals.
SUBSTANCE: present invention refers to solid pharmaceutical dispersion, which contains 3-(4-benzyloxyphenyl)-isoxazol-5-ylmethyl carbamic acid as the active ingredient, the water soluble polymer that has the glass transition temperature below the melting point of the active ingredient as the carrying agent and the softening agent. Solid dispersion is prepared by means of melt extrusion. Water-soluble polymer is selected from polyvinylpyrrolidone, hypromellose acetate succinate and combinations thereof. Softener is selected from the group, which consists of D-alpha-tocopheryl polyethylene glycol 1000 succinate, polyethylene glycol 400 and combinations thereof. Method for preparing the solid dispersion and the pharmaceutical composition that includes the solid dispersion are also disclosed and are intended for the treatment of degenerative brain disease.
EFFECT: solid dispersion of the present invention increases the solubility and dissolution rate of the active ingredient, which is the insoluble drug, for effective improvement of bioavailability during oral administration.
9 cl, 3 dwg, 13 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURONS OR NEURODEGENERATION | 2011 |
|
RU2722018C2 |
PHARMACEUTICAL COMPOSITION FOR INHIBITING NEURONAL APOPTOSIS OR NEURODEGENERATION | 2011 |
|
RU2586772C2 |
PRO-MEDICATION COMPOSITION FOR STRUGGLE AGAINST HEPAPATITIS C VIRUS | 2006 |
|
RU2435592C2 |
PERORAL SOLID DOSAGE FORM WITH MYCOPHENOLIC ACID OR ITS SALT FOR USE AS AN IMMUNODEPRESSANT FOR TREATMENT OR PREVENTION OF ORGAN OR TISSUE TRANSPLANT REJECTION AND METHOD FOR PRODUCTION THEREOF | 2016 |
|
RU2670447C2 |
SUBSTITUTED AZOL DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES, AND METHODS OF TREATING PARKINSON'S DISEASE WITH USING THESE DERIVATIVES | 2010 |
|
RU2578596C2 |
EXTRUDATE WITH SODIUM MYCOPHENOLATE TO PRODUCE PERORAL SOLID DOSAGE FORM | 2018 |
|
RU2723255C2 |
PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2809144C2 |
PHARMACEUTICAL COMPOSITION FOR HIV INFECTION TREATMENT | 2016 |
|
RU2619840C1 |
THE METHOD OF OBTAINING A PHARMACEUTICAL COMPOSITION WITH TACROLIMUS (VARIANTS) AND A PHARMACEUTICAL COMPOSITION OBTAINED BY THESE METHODS | 2022 |
|
RU2792098C1 |
COMPOSITION AND DOSAGE FORM CONTAINING SOLID OR SEMISOLID MATRIX | 2006 |
|
RU2423997C9 |
Authors
Dates
2018-03-05—Published
2013-11-07—Filed